Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1991 1
1993 1
1994 2
1995 1
1997 1
1998 1
1999 1
2000 4
2001 2
2002 6
2003 13
2004 6
2005 7
2006 8
2007 6
2008 9
2009 5
2010 8
2011 2
2012 4
2013 7
2014 6
2015 6
2016 2
2018 2
2019 3
2020 9
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

124 results
Results by year
Filters applied: . Clear all
Page 1
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S, Rücker G, Eberhart LH, Pace NL, Hartl HM, Jordan OL, Mayer D, Riemer M, Schaefer MS, Raj D, Backhaus I, Helf A, Schlesinger T, Kienbaum P, Kranke P. Weibel S, et al. Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2. Cochrane Database Syst Rev. 2020. PMID: 33075160 Free PMC article.
The certainty of evidence for SAEs when using one of the best and most reliable anti-vomiting drugs (aprepitant, ramosetron, granisetron, dexamethasone, ondansetron, and droperidol compared to placebo) ranged from very low to low. Droperidol (RR 0.88, 95% CI 0.08 to …
The certainty of evidence for SAEs when using one of the best and most reliable anti-vomiting drugs (aprepitant, ramosetron, granisetron, de …
Effectiveness and safety of droperidol in a United States emergency department.
Gaw CM, Cabrera D, Bellolio F, Mattson AE, Lohse CM, Jeffery MM. Gaw CM, et al. Am J Emerg Med. 2020 Jul;38(7):1310-1314. doi: 10.1016/j.ajem.2019.09.007. Epub 2019 Nov 25. Am J Emerg Med. 2020. PMID: 31831345
Food and Drug Administration required a black box warning in response to case reports of QT prolongation and potential fatal arrhythmias. The aim of this study was to evaluate the effectiveness and safety of droperidol in patients presenting to a United States Emerg …
Food and Drug Administration required a black box warning in response to case reports of QT prolongation and potential fatal arrhythm …
Antiemetic therapy for nausea and vomiting in the emergency department.
Patanwala AE, Amini R, Hays DP, Rosen P. Patanwala AE, et al. J Emerg Med. 2010 Sep;39(3):330-6. doi: 10.1016/j.jemermed.2009.08.060. Epub 2009 Dec 21. J Emerg Med. 2010. PMID: 20022195 Review.
OBJECTIVE: The objective of this article is to briefly review the evidence supporting the use of antiemetic agents for the treatment of nausea or vomiting for adults in the ED, and to provide recommendations to help guide therapy. DISCUSSION: The antiemetic agents studied include …
OBJECTIVE: The objective of this article is to briefly review the evidence supporting the use of antiemetic agents for the treatment of naus …
American Academy of Emergency Medicine Position Statement: Safety of Droperidol Use in the Emergency Department.
Perkins J, Ho JD, Vilke GM, DeMers G. Perkins J, et al. J Emerg Med. 2015 Jul;49(1):91-7. doi: 10.1016/j.jemermed.2014.12.024. Epub 2015 Mar 30. J Emerg Med. 2015. PMID: 25837231 Review.
QT prolongation is a well-known adverse effect of this class of medications. Of importance to note, QT prolongation is noted with multiple medication classes, and droperidol increases QT interval in a dose-dependent fashion among susceptible individual
QT prolongation is a well-known adverse effect of this class of medications. Of importance to note, QT prolongation is noted w
Reintegrating droperidol into emergency medicine practice.
Mattson A, Friend K, Brown CS, Cabrera D. Mattson A, et al. Am J Health Syst Pharm. 2020 Oct 30;77(22):1838-1845. doi: 10.1093/ajhp/zxaa271. Am J Health Syst Pharm. 2020. PMID: 32839811 Review.
SUMMARY: In 2001 the US Food and Drug Administration (FDA) mandated a boxed warning in the labeling of droperidol after reports of QT interval prolongation associated with droperidol use. ...Healthcare professionals can adopt droperidol for use in clin …
SUMMARY: In 2001 the US Food and Drug Administration (FDA) mandated a boxed warning in the labeling of droperidol after reports of …
The Incidence of QT Prolongation and Torsades des Pointes in Patients Receiving Droperidol in an Urban Emergency Department.
Cole JB, Lee SC, Martel ML, Smith SW, Biros MH, Miner JR. Cole JB, et al. West J Emerg Med. 2020 Jul 2;21(4):728-736. doi: 10.5811/westjem.2020.4.47036. West J Emerg Med. 2020. PMID: 32726229 Free PMC article.
INTRODUCTION: Droperidol carries a boxed warning from the United States Food and Drug Administration for QT prolongation and torsades des pointes (TdP). ...Thus, the objective of this study was to report the incidence of QT prolongation or TdP in patie …
INTRODUCTION: Droperidol carries a boxed warning from the United States Food and Drug Administration for QT prolongation and …
The Safety and Effectiveness of Droperidol for Sedation of Acute Behavioral Disturbance in the Emergency Department.
Calver L, Page CB, Downes MA, Chan B, Kinnear F, Wheatley L, Spain D, Isbister GK. Calver L, et al. Ann Emerg Med. 2015 Sep;66(3):230-238.e1. doi: 10.1016/j.annemergmed.2015.03.016. Epub 2015 Apr 15. Ann Emerg Med. 2015. PMID: 25890395
Thirteen of the 1,009 patients had an abnormal QT (1.3%; 95% confidence interval 0.7% to 2.3%), but 7 of these had another cause attributed for prolonged QT (methadone, escitalopram, amiodarone, or preexisting). ...There is no evidence of increased risk for QT
Thirteen of the 1,009 patients had an abnormal QT (1.3%; 95% confidence interval 0.7% to 2.3%), but 7 of these had another cause attr …
Droperidol, QT prolongation, and sudden death: what is the evidence?
Kao LW, Kirk MA, Evers SJ, Rosenfeld SH. Kao LW, et al. Ann Emerg Med. 2003 Apr;41(4):546-58. doi: 10.1067/mem.2003.110. Ann Emerg Med. 2003. PMID: 12658255 Review.
Its labeling has recently been revised, with a black box warning for cases of QT prolongation leading to torsades de pointes and death. A black box warning is applied when serious adverse drug reactions are uncovered for medications. We sought to examine the evidenc …
Its labeling has recently been revised, with a black box warning for cases of QT prolongation leading to torsades de pointes a …
Psychotropic drugs and the ECG: focus on the QTc interval.
Goodnick PJ, Jerry J, Parra F. Goodnick PJ, et al. Expert Opin Pharmacother. 2002 May;3(5):479-98. doi: 10.1517/14656566.3.5.479. Expert Opin Pharmacother. 2002. PMID: 11996627 Review.
The QT interval measuring depolarisation and repolarisation has, when lengthened, been implicated as a risk factor for the development of torsades de pointes and sudden death, particularly in patients predisposed to these complications due to cardiovascular impairme …
The QT interval measuring depolarisation and repolarisation has, when lengthened, been implicated as a risk factor for the developmen …
Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study.
Isbister GK, Calver LA, Page CB, Stokes B, Bryant JL, Downes MA. Isbister GK, et al. Ann Emerg Med. 2010 Oct;56(4):392-401.e1. doi: 10.1016/j.annemergmed.2010.05.037. Ann Emerg Med. 2010. PMID: 20868907 Clinical Trial.
An abnormal QT occurred in 2 of 31 (6%; 95% CI 1% to 23%) droperidol patients, which was not different from the other groups. ...Midazolam caused more adverse effects because of oversedation, and there was no evidence of QT prolongation associated with dro
An abnormal QT occurred in 2 of 31 (6%; 95% CI 1% to 23%) droperidol patients, which was not different from the other groups. …
124 results